Boehringer Pays $95M To Settle FCA Suit Over Drug Marketing
Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle a former employee's False Claims Act suit accusing the company of off-label marketing and kickbacks related to stroke-prevention drug Aggrenox and...To view the full article, register now.
Already a subscriber? Click here to view full article